TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07713602: A Multi-centre, Open-label, Non-comparative Study to Assess Safety and Clinical Response With Coartem® Baby Dispersible Tablets in Paediatric Patients (≥ 2 to <5 kg) With Uncomplicated Malaria Due to Plasmodium Falciparu

Sponsor: Novartis Pharmaceuticals · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$743,680

Rescue Site Savings

+$478,080

Unlock Full NCT07713602 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07713602 Rescue Dossier →